IN THE CLAIMS

Please cancel claims 1, 4 and 18-24, without prejudice or disclaimer.

Please amend the claims pursuant to 37 C.F.R. §1.121 as follows (see the accompanying "marked up" version pursuant to §1.121):

2. (Amended) The method of claim ~~5~~ 1, wherein said composition is administered for at least three times.

3. (Amended) The method of claim ~~5~~ 1, wherein said composition is administered for at least six times.

5. (Amended) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to said patient a composition comprising a tumor cell or tumor cell extract with an adjuvant, wherein the tumor cell or tumor cell extract is:

(i) conjugated to a hapten;

(ii) of the same tumor type as the patient's tumor;

(iii) not allogeneic to said patient, and

(iv) incapable of growing in the body of the patient after injection; and

repeating said administration at weekly intervals,

wherein a therapeutically effective amount of cyclophosphamice is administered only prior to the first administration of the composition, and wherein the composition, when administered with the adjuvant, elicits an anti-tumor response.

6. (Amended) The method of claim 5 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M^2 of cyclophosphamide.

7. (Amended) The method of claim 5 wherein said tumor cell or extract is selected from the group consisting of melanoma, lung, colon, breast, kidney, prostate, ovarian and leukemia tumor cell or extract.

8. (Amended) The method of claim 5 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

12. (Amended) The method of claim 5 wherein said adjuvant is selected from the group consisting of Bacillus Calmette-Guerin, QS-21, detoxified endotoxin and a cytokine.

13. (Amended) The method of claim 5 further comprising sensitizing said mammalian patient with a therapeutically effective amount of the hapten prior to administering said composition.

14. (Amended) The method of claim 5 wherein said mammalian patient is not sensitized to said hapten prior to administration of said composition.

15. (Amended) The method of claim 5 wherein said mammalian patient is a human.

16. (Twice amended) The method of claim 5 wherein said composition comprises at least 10^6 tumor cells or cell equivalents extract per dose.

17. (Amended) The method of claim 5 wherein said anti-tumor response is at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T lymphocytes, stable disease and prolongation of patient survival.

Please add the following new claims:

25. (New) The method of claim 1, wherein the cyclophosphamide is administered 3 days prior to administration of the composition.

26. (New) The method of claim 1, wherein the composition comprises a maximum of 7.5×10^6 cells or cell equivalents per dose.